1292290-38-0

Usage

Uses

Used in Medicinal Chemistry:
(3S)-3-(4-[4-(1′H-spiro[indene-1,4′-piperidine]-1′-ylmethyl)benzyl]oxyphenyl)hex-4-ynoic acid is used as a potential active pharmaceutical ingredient for its unique structure and possible biological activity, which may contribute to the development of new drugs.
Used in Drug Development:
In the pharmaceutical industry, (3S)-3-(4-[4-(1′H-spiro[indene-1,4′-piperidine]-1′-ylmethyl)benzyl]oxyphenyl)hex-4-ynoic acid is utilized as a compound in the research and development of novel therapeutic agents, given its distinctive molecular architecture that could lead to innovative medicinal applications.
Further research and study are essential to fully comprehend the properties and potential applications of (3S)-3-(4-{[4-(1′H-spiro[indene-1,4′-piperidine]-1′-ylmethyl)benzyl]oxy}phenyl)hex-4-ynoic acid, as its complex nature and the presence of multiple functional groups suggest a wide range of possible interactions with biological systems.

Upstream product

• 137730-67-7 spiro(1H-indene-1,4'-piperidine) hydrochloride 
• 1292291-39-4 ethyl (S)-3-(4-((4-(spiro[indene-1,4'-piperidin]-1'-ylmethyl)benzyl)oxy)phenyl)hex-4-ynoate 
• 1292291-10-1 (4-(spiro[indene-1,4'-piperidin]-1'-ylmethyl)phenyl)methanol 
• 865233-35-8 (3S)-3-(4-hydroxy-phenyl)-hex-4-ynoic acid 
• 865233-33-6 (+/-)-5-[1-(4-hydroxy-phenyl)-but-2-ynyl]-2,2-dimethyl-[1,3]dioxane-4,6-dione 
• 865233-34-7 4-hydroxy-β-1-propyn-1-ylbenzenepropanoic acid 
• 17474-27-0 5-(4-hydroxy-benzylidene)-2,2-dimethyl-[1,3]dioxane-4,6-dione 
• 71831-21-5 4-(bromomethyl)benzyl alcohol 
• 2417-72-3 Methyl 4-(bromomethyl)benzoate 
• 123-08-0 4-hydroxy-benzaldehyde 

Relevant academic research and scientific papers

The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)

The G protein-coupled receptor 40 (GPR40) also known as free fatty acid receptor 1 (FFAR1) is highly expressed in pancreatic, islet β-cells and responds to endogenous fatty acids, resulting in amplification of insulin secretion only in the presence of elevated glucose levels. Hypothesis driven structural modifications to endogenous FFAs, focused on breaking planarity and reducing lipophilicity, led to the identification of spiropiperidine and tetrahydroquinoline acid derivatives as GPR40 agonists with unique pharmacology, selectivity, and pharmacokinetic properties. Compounds 1 (LY2881835), 2 (LY2922083), and 3 (LY2922470) demonstrated potent, efficacious, and durable dose-dependent reductions in glucose levels along with significant increases in insulin and GLP-1 secretion during preclinical testing. A clinical study with 3 administered to subjects with T2DM provided proof of concept of 3 as a potential glucose-lowering therapy. This manuscript summarizes the scientific rationale, medicinal chemistry, preclinical, and early development data of this new class of GPR40 agonists.

Novel Spiropiperidine Compounds

A compound of the formula: or a pharmaceutically acceptable salt thereof as well as a pharmaceutical composition, and a method for treating diabetes.